Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fir ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems long and uncertain, according to a news release.

CIDRAP: Early-Life Infection Burden Continues Throughout Childhood, New Data Reveal New data from researchers in Denmark suggest that children who have a lot of common infections early in life ...

Imagine a world where the mind remains sharp, even as the years pass by. Scientists are on the brink of a breakthrough that ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track ...

represents an important step toward finding a treatment for frontotemporal dementia. If further research confirms these findings, it could pave the way for new therapies that improve the lives of ...

Warren Foundation then enabled us to partner with DavosPharma to conduct critical early-stage studies and earn approval from the FDA as an investigational new drug, paving the way for the Alzheimer's ...